Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001628280-25-053613
Filing Date
2025-11-21
Accepted
2025-11-21 16:29:40
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3857
  Complete submission text file 0001628280-25-053613.txt   5352
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Subject) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 000-23186 | Film No.: 251508401
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O GLYCOMIMETICS, INC. 401 PROFESSIONAL DRIVE, SUITE 250 GAITHERSBURG MD 20879
Business Address
Thackray Helen M. (Reporting) CIK: 0001589725 (see all company filings)

Type: 144